ArticleClinical rheumatology2016
Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases.
Article in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.Current rheumatology reports · 2016Pooled it
- Challenging endovascular treatment for the patient with chronic limb threatening ischemia due to antiphospholipid syndrome.Journal of cardiology cases · 2021Article
- Would you use novel oral anticoagulants (NOACs) for thromboprophylaxis in patients with an underlying hypercoagulable state? A literature review through a case report.BMJ case reports · 2020Review
- Role of direct oral anticoagulants in patients with kidney disease.Kidney international · 2020Review
- Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review.Archives of rheumatology · 2020Article
- Anticoagulating patients with high-risk acquired thrombophilias.Hematology. American Society of Hematology. Education Program · 2018Review
- Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.Journal of the American Heart Association · 2018Review
- Diagnosis and management of the antiphospholipid syndrome.Blood reviews · 2017Review
- Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature.Clinical medicine & research · 2017Review
- The use of direct oral anticoagulants in inherited thrombophilia.Journal of thrombosis and thrombolysis · 2017Review
- Direct oral anticoagulants in hypercoagulable states.Journal of thrombosis and thrombolysis · 2017Article
- Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome.Hospital pharmacy · 2016Article
- Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?Current rheumatology reports · 2016Review
- Emerging Therapies in Antiphospholipid Syndrome.Current rheumatology reports · 2016Review
- Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.Drugs · 2016Review
- Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases.Reumatologia · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment for antiphospholipid syndrome (APS) with thrombotic manifestation is long-term anticoagulation. Vitamin K antagonists (VKA) are usually the agents of choice. However, VKA limitations, such as unpredictable anticoagulation effects due to interaction with diet and other drugs, require regular monitoring. This may impact on patients' quality of life. Since the approval of new oral anticoagulants (NOAC) for non-valvular atrial fibrillation and deep vein thrombosis prevention, much has been speculated about its use in APS patients. We report here a series of eight APS patients with failure of thrombotic prevention during rivaroxaban use. All patients had venous thrombosis as the initial manifestation of APS, and two of them also had arterial manifestations. Three patients had triple antibody positivity. Five patients developed arterial events during the treatment with rivaroxaban. Until the results of ongoing trials of rivaroxaban for APS are presented, NOAC should not be recommended to APS patients. Our preliminary experience as well cases previously reported in the literature suggest that there is a high-risk group that is less protected with rivaroxaban, namely those with previous arterial thrombosis or triple positivity. VKA remains to be the mainstay treatment for thrombotic APS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.